CY1111180T1 - Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης - Google Patents
Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπηςInfo
- Publication number
- CY1111180T1 CY1111180T1 CY20111100152T CY111100152T CY1111180T1 CY 1111180 T1 CY1111180 T1 CY 1111180T1 CY 20111100152 T CY20111100152 T CY 20111100152T CY 111100152 T CY111100152 T CY 111100152T CY 1111180 T1 CY1111180 T1 CY 1111180T1
- Authority
- CY
- Cyprus
- Prior art keywords
- flual
- vaccines
- risks
- reduction
- possible medicine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Οι ιοί γρίπης που είναι κατάλληλοι για χρήση στην παρασκευή ανθρώπινων εμβολίων παραδοσιακά αναπτύσσονταν πάνω σε εμβρυονισμένα ωά όρνιθας, ενώ με τις σύγχρονες τεχνικές ο ιός αναπτύσσεται εντός καλλιέργειας θηλαστικοκυττάρων, π.χ. πάνω σε κυτταρικές σειρές Vero, MDCK ή PER.C6. Ο εφευρέτης διαπίστωσε ότι οι συνθήκες που χρησιμοποιούνται για την καλλιέργεια του ιού γρίπης 5 αυξάνουν τον κίνδυνο ανάπτυξης παθογόνων, πέραν του ιού γρίπης, εντός των κυτταρικών σειρών και ταυτοποίησε συγκεκριμένους κινδύνους μόλυνσης. Επομένως κατά την παραγωγή μπορούν να πραγματοποιηθούν κατάλληλες εξετάσεις για την επιβεβαίωση της ασφάλειας και την αποφυγή ιατρογενών μολύνσεων.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04255471 | 2004-09-09 | ||
EP05795012A EP1789084B1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111180T1 true CY1111180T1 (el) | 2015-06-11 |
Family
ID=35520177
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100152T CY1111180T1 (el) | 2004-09-09 | 2011-02-09 | Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης |
CY20111100197T CY1111208T1 (el) | 2004-09-09 | 2011-02-16 | Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης |
CY20121100706T CY1113225T1 (el) | 2004-09-09 | 2012-08-07 | Μειωση πιθανων ιατρογενων κινδυνων που συνδυαζονται με εμβολια γριπης |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100197T CY1111208T1 (el) | 2004-09-09 | 2011-02-16 | Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης |
CY20121100706T CY1113225T1 (el) | 2004-09-09 | 2012-08-07 | Μειωση πιθανων ιατρογενων κινδυνων που συνδυαζονται με εμβολια γριπης |
Country Status (16)
Country | Link |
---|---|
US (6) | US8119337B2 (el) |
EP (5) | EP2578229B1 (el) |
JP (7) | JP2008512443A (el) |
AT (2) | ATE488248T1 (el) |
CA (2) | CA2890962A1 (el) |
CY (3) | CY1111180T1 (el) |
DE (3) | DE602005025170D1 (el) |
DK (4) | DK2236155T3 (el) |
ES (4) | ES2357747T3 (el) |
HK (2) | HK1105364A1 (el) |
HR (4) | HRP20100673T1 (el) |
PL (4) | PL2179744T3 (el) |
PT (4) | PT2179744E (el) |
RS (3) | RS52400B (el) |
SI (4) | SI2578229T1 (el) |
WO (1) | WO2006027698A1 (el) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2578229B1 (en) | 2004-09-09 | 2013-07-10 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential iatrogenic risks associated with vaccine antigens |
ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
PL2301572T3 (pl) | 2005-11-01 | 2015-02-27 | Novartis Influenza Vaccines Marburg Gmbh | Szczepionki wirusowe otrzymane z komórek o niskim poziomie pozostałości DNA komórkowego |
NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
WO2007052061A2 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
EP2368572B1 (en) | 2005-11-04 | 2020-03-04 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
EP1951298A1 (en) | 2005-11-04 | 2008-08-06 | Novartis Vaccines and Diagnostics S.r.l. | Adjuvanted influenza vaccines including cytokine-inducing agents |
PT2478916T (pt) | 2006-01-27 | 2020-07-03 | Seqirus Uk Ltd | Vacinas de influenza que contêm hemaglutinina e proteínas da matriz |
EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
EP3456348A1 (en) | 2006-09-11 | 2019-03-20 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
ES2480491T3 (es) | 2006-12-06 | 2014-07-28 | Novartis Ag | Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe |
WO2008156778A2 (en) | 2007-06-18 | 2008-12-24 | Tokiko Watanabe | Influenza m2 protein mutant viruses as live influenza attenuated vaccines |
EP2484377A1 (en) | 2007-06-27 | 2012-08-08 | Novartis AG | Low-additive influenza vaccines |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
KR20100135766A (ko) | 2008-03-18 | 2010-12-27 | 노파르티스 아게 | 인플루엔자 바이러스 백신 항원 제조의 개선 |
JP2012507272A (ja) | 2008-11-05 | 2012-03-29 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 新規な方法 |
EP2942062A1 (en) | 2009-02-10 | 2015-11-11 | Novartis AG | Influenza vaccine regimens for pandemic-associated strains |
CA2752041A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccines with increased amounts of h3 antigen |
CA2751379C (en) | 2009-02-10 | 2018-06-12 | Novartis Ag | Influenza vaccines with reduced amounts of squalene |
KR20120027276A (ko) | 2009-04-27 | 2012-03-21 | 노파르티스 아게 | 인플루엔자를 예방하기 위한 면역증강된 백신 |
CA2773637A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US20130039943A1 (en) * | 2010-05-03 | 2013-02-14 | Bruno Rene Andre | Novel method |
WO2011145081A1 (en) | 2010-05-21 | 2011-11-24 | Novartis Ag | Influenza virus reassortment method |
AU2011262312B2 (en) | 2010-06-01 | 2015-05-28 | Novartis Ag | Concentration and lyophilization of influenza vaccine antigens |
WO2011151723A2 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens without lyophilization |
GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
ES2531577T3 (es) | 2010-08-20 | 2015-03-17 | Novartis Ag | Conjuntos de agujas para la administración de vacuna soluble contra la gripe |
WO2012032482A1 (en) | 2010-09-07 | 2012-03-15 | Novartis Ag | Generic assays for detection of mammalian reovirus |
ES2572391T3 (es) * | 2011-02-25 | 2016-05-31 | Novartis Ag | Control exógeno interno positivo para la detección de virus |
EP2768528A1 (en) | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
WO2013088367A1 (en) * | 2011-12-12 | 2013-06-20 | Novartis Ag | Assay for influenza virus hemagglutinins |
GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
WO2015118146A1 (en) | 2014-02-10 | 2015-08-13 | Univercells Nv | System, apparatus and method for biomolecules production |
RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
MA40920A (fr) | 2014-11-07 | 2017-09-12 | Takeda Vaccines Inc | Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci |
AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
US11013795B2 (en) | 2015-06-26 | 2021-05-25 | Seqirus UK Limited | Antigenically matched influenza vaccines |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
KR102576962B1 (ko) | 2015-07-07 | 2023-09-11 | 세퀴러스 유케이 리미티드 | 인플루엔자 효능 검정 |
US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
WO2019090233A2 (en) | 2017-11-03 | 2019-05-09 | Takeda Vaccines, Inc. | Method for inactivating zika virus and for determining the completeness of inactivation |
EP3867412A1 (en) * | 2018-10-15 | 2021-08-25 | REGENXBIO Inc. | Method for measuring the infectivity of replication defective viral vectors and viruses |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
CA3137652A1 (en) | 2019-05-08 | 2020-11-12 | Takeda Vaccines, Inc. | Inactivated virus compositions and zika vaccine formulations |
WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
KR20220128613A (ko) | 2019-11-18 | 2022-09-21 | 세퀴러스 피티와이 리미티드 | 재배열 인플루엔자 바이러스의 제조 방법 |
EP4093415A1 (en) * | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized na |
US20240139306A1 (en) * | 2021-03-01 | 2024-05-02 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and vaccines thereof |
CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
WO2023154043A1 (en) | 2022-02-09 | 2023-08-17 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4193991A (en) * | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
EP0261955A3 (en) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Process for immobilization of dna |
US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
IL99851A (en) | 1990-10-30 | 1996-06-18 | Daiichi Seiyaku Co | Moramildipeptide derivatives and an influenza vaccine containing them |
JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ3型ウイルス感染症、牛rsウイルス感染症および牛アデノ7型ウイルス感染症5種混合生ワクチン |
IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
EP0684838A1 (en) | 1993-02-19 | 1995-12-06 | Smithkline Beecham Corporation | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
EP1213030B1 (en) | 1994-11-10 | 2009-04-22 | Baxter Healthcare SA | Method for producing biologicals in protein-free culture |
US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
PT2363488E (pt) * | 1997-12-11 | 2015-01-13 | Univ Belfast | Síndrome multi-sistémica do definhamento pós-desmame de porcos |
GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
US8012736B2 (en) * | 2002-04-26 | 2011-09-06 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
EP1520008B1 (en) * | 2002-07-09 | 2012-09-05 | Baxter International Inc. | Animal protein free media for cultivation of cells |
JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
US20040176272A1 (en) | 2003-01-30 | 2004-09-09 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
EP2494986A1 (en) * | 2003-04-25 | 2012-09-05 | MedImmune Vaccines, Inc. | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
EP2578229B1 (en) * | 2004-09-09 | 2013-07-10 | Novartis Vaccines and Diagnostics GmbH | Decreasing potential iatrogenic risks associated with vaccine antigens |
NZ599585A (en) | 2007-06-14 | 2013-12-20 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
-
2005
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es active Active
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es active Active
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en active Active
- 2005-09-09 RS RS20120317A patent/RS52400B/en unknown
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en active Active
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de active Active
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en active Application Filing
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es active Active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de active Active
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 RS RSP20110075 patent/RS51721B/en unknown
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 RS RSP20110084 patent/RS51665B/en unknown
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es active Active
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en active Active
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
-
2007
- 2007-11-26 HK HK07112869.6A patent/HK1105364A1/xx not_active IP Right Cessation
-
2010
- 2010-09-30 HK HK10109406A patent/HK1144374A1/xx not_active IP Right Cessation
- 2010-12-06 HR HR20100673T patent/HRP20100673T1/hr unknown
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en active Active
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en active Active
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en active Active
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111208T1 (el) | Ελαττωση δυνητικων ιατρογενων κινδυνων συναφων με τα εμβολια γριπης | |
NZ577405A (en) | Vaccines including antigen from four strains of influenza virus | |
CL2011000913A1 (es) | Vacuna combinada estable y completamente liquida que comprende antigenos difterico, tetanico, pertusico de celulas completas, y virus de poliomielitis y opcionalmente uno o mas antigenos seleccionados entre haemophilus influenzae y hepatitis; y proceso de fabricacion. | |
PL1951300T3 (pl) | Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant | |
IL195798A0 (en) | Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais) | |
WO2010019262A3 (en) | Polyvalent vaccine | |
NZ603863A (en) | Concentration and lyophilization of influenza vaccine antigens | |
WO2006063053A3 (en) | Methods of producing influenza vaccine compositions | |
DK1796717T3 (da) | Kombinationsvaccine | |
PL2368572T3 (pl) | Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej | |
BRPI0412913A (pt) | meio para tratamento de infecções por leishmaniose | |
MX2012002702A (es) | Vacuna de herpesvirus bovino. | |
EP2175271A4 (en) | ASSAY PROCEDURE ON A CAT STICKED WITH A VACCINE AGAINST FELINES IMMUNODEFICIENCY AND ANTIGEN FOR USE IN THE TEST | |
UA38029U (ru) | Способ инактивации бактерий при производстве вакцин | |
UA35018U (ru) | Способ иммунокоррекции больных ветряной оспой с наличием вторичного иммунодефицита | |
UA35024U (ru) | Способ лечения взрослых больных хроническими гепатитами невирусной этиологии | |
UA75136U (ru) | Способ биолазеротерапии у детей больных бронхиальной астмой |